Glenmark bags USFDA nod for Metronidazole Vaginal Gel

Published On 2022-01-28 05:42 GMT   |   Update On 2022-01-28 05:42 GMT
Advertisement

Mumbai: Drug maker, Glenmark Pharmaceuticals Inc., USA  has received final approval from the United States Food & Drug Administration (USFDA) for Metronidazole Vaginal Gel, 0.75%.

The product is a generic version of MetroGel-Vaginal Gel, 0.75%, of Bausch Health US, LLC.

According to IQVIA sales data for the 12 month period ending November 2021, the MetroGel- Vaginal Gel, 0.75% market achieved annual sales of approximately $60.4 million*.
Advertisement
Glenmark's current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 46 ANDA's pending approval with the U.S. FDA.
In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Read also: Glenmark bags USFDA nod for generic version of Ziac Tablets

Glenmark Pharmaceuticals Limited is a global research-led pharmaceutical company with presence across generics, specialty and OTC businesses and with operations in over 50 countries.

Glenmark's key therapy focus areas globally are respiratory, dermatology and oncology. The company has been listed on the Dow Jones Sustainability Index (DJSI), under the category of emerging markets for four consecutive years in a row; most recently in 2021.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News